Louis Bonavita, MD
Family Medicine · East Syracuse, NYNPI 1225025109
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $530,218 of the $674,350 with a category attached, or 78.6%. 60 manufacturers reported payments, led by AbbVie at 28.0% of the total. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,358 payments — averaging $285.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$189K
- Amgen$180K
- Bayer$78K
- Phathom Pharmaceuticals, Inc.$65K
- Johnson & Johnson$47K
- Otsuka America Pharmaceutical, Inc.$35K
- plus $81K from 54 others
What the payments were for
- Consulting fees$22,4223%
- Speaking & faculty fees$530,21879%
- Travel & lodging$84,68713%
- Food & beverage$36,8095%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$674,350 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $368,571 |
| JardianceEmpagliflozin | 257 | $363,021 |
| Enbrel SureclickEtanercept | 23 | $243,607 |
| FarxigaDapagliflozin Propanediol | 166 | $221,984 |
| XareltoRivaroxaban | 175 | $214,165 |
| KerendiaFinerenone | 188 | $214,016 |
| EliquisApixaban | 180 | $192,752 |
| MounjaroTirzepatide | 125 | $181,603 |
| EnbrelEtanercept | 15 | $168,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $145,781 |
| JanuviaSitagliptin Phosphate | 110 | $120,400 |
| TrulicityDulaglutide | 92 | $108,124 |
| RexultiBrexpiprazole | 49 | $95,981 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $90,924 |
| HumiraAdalimumab | 13 | $88,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,489 | $409,638277 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $676 | $380,475273 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $16,256 | $299,882293 claims |
| Lilly USA, LLCMounjaro, Trulicity | $7,684 | $289,727217 claims |
| AmgenEnbrel, Otezla, Prolia | $180,070 | $285,36355 claims |
| AbbVieHumira, Vraylar, Linzess, Savella, Restasis | $188,994 | $260,637163 claims |
| Johnson & JohnsonXarelto, Invokana | $46,597 | $248,216199 claims |
| BayerKerendia | $77,917 | $214,016188 claims |
| PfizerEliquis | $11,908 | $192,752180 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,398 | $185,995244 claims |
| MerckJanuvia, Janumet Xr | $471 | $140,600135 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $34,534 | $95,98149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in East Syracuse
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Sean FentonStaten Island$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.